xtrathyroid extension (ETE) is common in patients with differentiated thyroid cancer (DTC) and is reported in up to 30% of patients (1) . Although gross ETE, defined as a macroscopic spread of the tumor apparent on imaging or during surgery, is well established as a risk factor for both survival and recurrence of disease, there is an ongoing debate on the prognostic importance of minimal ETE (mETE), detected only on histological examination. The 2015 American Thyroid Association guidelines grouped tumors with mETE in the indeterminate risk of recurrence category, citing studies with a 3% to 9% risk of recurrence, a range that is between low to intermediate risk (2) (3) (4) (5) (6) (7) . However, the interpretation of these and other studies evaluating mETE is complex, given differences in definition of mETE, tumor size (microscopic vs macroscopic disease), and inclusion of patients with and without lymph node metastases (N1 and N0 disease) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
In terms of survival, mETE was previously regarded as a negative predictor according to the seventh edition of the American Joint Committee on Cancer (AJCC) TMN staging classification, upstaging patients .45 years of age from stage I to stage III disease. However, because there is no clear evidence showing the effect of mETE on survival, mETE detected only on histological examination was removed from the T3 definition in the 8th edition of the AJCC classification and therefore has no impact on either T category or overall stage (17, 18) .
In light of the conflicting data on the recurrence risk conferred by mETE, we performed a systematic review and meta-analysis to assess the impact of mETE on outcome in patients with DTC.
Methods

Data sources
We searched PubMed (January 1966 to June 2017), CENTRAL (The Cochrane library, up to June 2017), and conference proceedings in endocrinology, oncology, and thyroid surgery. The terms "papillary thyroid cancer" and similar, "minimal extrathyroidal extension" and similar, and "outcome" and similar were crossed. We scanned references of all included trials and reviews identified for additional studies.
Study selection and data extraction
Studies comparing outcomes in adult patients with DTC with and without mETE were included. We included trials regardless of publication status and language. Studies in which the prognostic impact of mETE was not the primary outcome were included only if sufficient data were presented on patients with or without mETE (including baseline characteristics, definition of mETE, follow-up duration, and recurrence). Studies with no distinction between minimal and gross extrathyroidal extension or between T3 subcategories (mETE vs size .4 cm) were excluded.
Data extraction and quality assessment
Two reviewers (T.D.-C., E.R.) independently extracted data from the included trials. In the case of any disagreement between the two reviewers, a third reviewer (A.A.) extracted the data. We contacted the authors of trials for missing data, when necessary. Two independent reviewers assessed the trials for methodological quality.
Definition of outcomes
Primary outcomes included recurrent or persistent disease at the end of follow-up, disease-related mortality, and overall mortality. Subgroup analysis was performed for patients with N0 and N1 disease, for patients with papillary thyroid carcinoma ,1 cm (micro-PTC), and for age younger and older than 45 or 55 (as available in the included studies).
Data synthesis and analysis
We analyzed data by calculating the odds ratio (OR) for each trial, with uncertainty expressed using 95% confidence intervals (CIs) [Review Manager (RevMan), version 5.2, for Windows; The Cochrane Collaboration, Oxford, United Kingdom]. We used a fixed-effect model using the MantelHaenszel method for pooling trial results throughout the review, unless statistically significant heterogeneity was found, in which case we chose a random-effects model. We assessed the heterogeneity of trial results by inspecting graphical presentations and calculating a x 2 test of heterogeneity and an I 2 measure of inconsistency. We explored potential sources of heterogeneity through predefined subgroup analyses.
Results
Description of the studies
Thirteen studies including 23,816 patients fulfilled the inclusion criteria comparing outcome of patients with DTC with and without mETE. Twelve studies were identified by literature search and one by screening of conference proceedings for which additional unpublished data were provided by the authors (unpublished data) (19) . Reasons for exclusion are detailed in Fig. 1 . All studies were retrospective and published between 2001 and 2016 (Table 1) . Twelve studies included single-center data, and one analyzed data from the Surveillance, Epidemiology, and End Results database. Eighty-one percent of included patients were females, and the median follow-up was 86 months. mETE definition varied between studies and included pathologic ETE not seen by surgeon (n = 6), perithyroid soft tissue or strap muscles involvement (n = 4), or no clear definition (n = 3). Ten studies included patients with and without lymph node involvement (N1/N0 disease), of which four had separate subanalysis for the N0 and N1 groups and three studies included only patients without lymph node involvement (N0 disease). The average tumor size ranged between 5 and 20 mm, with three studies including microcarcinomas only. Extent of surgery and radioiodine (RAI) ablation varied between studies as detailed in Table 1 . Recurrence data were provided in 11 studies, and mortality data were provided in eight studies.
Risk of recurrence: patients with N0 disease
Seven studies evaluated the impact of mETE on recurrence in 5405 patients with DTC with N0 disease at baseline (no ETE in 4833 subjects, mETE in 572 subjects) (1, 4, (8) (9) (10) (11) 19) . mETE in patients with N0 disease was associated with increased risk of recurrence (OR, 1.73; 95% CI. 1.03 to 2.92) (Fig. 2) . This difference was mostly from an outlier study by Chéreau et al. (1) , without which mETE did not confer increased risk (six studies: OR, 1.37; 95% CI, 0.74 to 2.53). Assessment of this outlier study did not reveal a substantial risk of bias apart from its retrospective design, and treatment was homogenous with total thyroidectomy and RAI ablation in 96% of patients.
The absolute risk of recurrence was 2.2% in patients without tumor extension and 3.5% in patients with mETE (P = 0.04) during follow-up periods ranging between 55.8 (8) and 207 months (10) . Routine total thyroidectomy and RAI ablation was performed in two studies (97% to 100% of patients, 100 mCi) (1, 19), with 1.3% risk of recurrence in patients without ETE and 3.7% risk in patients with mETE (P = 0.47). In one study, patients with micro-PTC had lobectomy alone (8) , with a 4.2% risk of recurrence in patients without extension and a 6.9% risk in patients with mETE (P = 0.3). In the four remaining studies, the extent of surgery and rate of RAI ablation were variable (total thyroidectomy in 58% to 77% of patients) according to physician discretion, with 2.2% risk of recurrence in patients without extension and 3.3% risk in patients with mETE (P = 0.5) (4, 9-11). One study assessed risk of recurrence in patients .45 years of age with mETE and size ,4 cm; the reported recurrence rate of 3.8% at 20 years was similar to outcome in younger patients (10) .
Risk of recurrence: mixed N1/N0 population
Eight studies assessed the impact of mETE on recurrence rates in 8659 patients with DTC with mixed N1/N0 population (no ETE in 6993 subjects, mETE in 1666 subjects) (1, 5, 6, 10, 11, (13) (14) (15) . Only one study provided recurrence data for the subgroup of N1 disease at presentation (11), whereas seven assessed outcome for the entire study population (1, 5, 6, 10, (13) (14) (15) . In the cohort of mixed N1/N0 disease, mETE resulted in a significantly higher risk of recurrence (OR, 1.82; 95% CI, 1.14 to 2.91; P = 0.01) (Fig. 3) . Notably, the risk of bias in this analysis is high because of unbalanced baseline characteristics between groups (patients were not matched). Because of high heterogeneity (I 2 = 67%), random effect analysis was used. The absolute risk of recurrence was 6.2% in patients without extension and 7% in patients with mETE (P = 0.01) during a follow-up period ranging between 62 (15) and 207 months (10) . This small difference is statistically significant because studies receive different statistical weight in the meta-analysis according to sample size. In four studies, total thyroidectomy and RAI ablation were performed in .90% of patients (1, 6, 13, 14) , with risk of recurrence of 2.3% in patients without extension and 4.8% in patients with mETE (P = 0.06). In the four other studies, the extent of surgery and the rate of RAI ablation were variable; lobectomy was the treatment of choice in none of the studies. The impact of age younger and older than 45 years was assessed in one study (which was reported in two manuscripts) (5, 16) , in which patients aged $45 with mETE did not have increased risk of recurrence.
Micro-PTC
Five studies assessed the impact of mETE on recurrence rates in patients with papillary microcarcinoma, including 2580 patients (no ETE in 2221 subjects, mETE in 359 subjects). Three studies assessed microcarcinoma with N0 disease, and two included microcarcinoma with mixed N0 and N1 disease. In patients with microscopic disease, there was no significant impact of mETE on recurrence rates (OR, 2.40; 95% CI, 0.95 to 6.03). The absolute risk of recurrence was 2% in patients without extension and 5.3% in patients with mETE (P = 0.06). In one study with patients who were treated with lobectomy (8), the risk of recurrence was 4.2% in patients without extension and 7% in patients with mETE (NS). In two studies in which 97% to 100% of patients had total thyroidectomy, one with RAI ablation (19) and one without (1), the risk of recurrence was 1.6% in patients without extension and 5% in patients with mETE (P , 0.01).
Mortality
The number of disease-related deaths was 49 of 6918 patients with no ETE, whereas there were no cases of disease-related deaths among 1258 subjects with mETE (Fig. 4) . Therefore, mETE had no impact on disease-related mortality (eight studies: OR, 0.5; 95% CI, 0.11 to 2.21; I 2 = 0%) (Fig. 3) . Unexpectedly, overall mortality was significantly higher in patients with no mETE (seven studies: OR, 1.34; 95% CI, 1.16 to 1.54; I 2 = 68%) because there were 270 cases of death of 2731 patients (9.8%) with mETE vs 1473 deaths in 16,849 patients (8.7%) without ETE.
Discussion
To guide risk stratification and treatment of patients with DTC and mETE, we performed a systematic review and meta-analyses evaluating 23,816 patients with and without disease extension. Our work stratified patients according to clinically relevant groups of patients with or without lymph node involvement (N0 or N1 disease) and a subgroup of microcarcinomas. Our results show that mETE significantly increases risk of recurrence in patients with both N0 and N1 disease compared with patients without extension (OR, 1.73 and 1.82, respectively). However, this statistically significant difference reflects a small absolute risk of recurrence. Specifically, in patients with mETE without lymph node involvement (N0 disease) in which detection of mETE often entails more aggressive surgery and RAI ablation, the recurrence risk was 2.2% in patients without extension and 3.5% in patients with mETE. Although different, both of these numbers are within the "low risk" end of the recurrence category, which is usually defined as ,5% (7).
The modified American Thyroid Association risk stratification system published in the 2015 guidelines define mETE as an intermediate risk feature, for which total thyroidectomy is recommended (recommendation 35) and RAI adjuvant therapy should be considered (recommendation 51) (7) . According to our data, in patients with N1 disease, the presence of mETE did increase the risk of recurrence further, yet tumors with mETE that did not have other adverse features have a low risk of recurrence both in studies in which all patients were treated with total thyroidectomy and RAI ablation (3.7% recurrence rate) (1, 19) and in studies in which patients were treated with either total thyroidectomy or lobectomy at the discretion of the treating physician (3.3% recurrence rate, total thyroidectomy in 58% to 77% of patients) (4, 9-11). In one study, patients with micro-PTC had lobectomy alone, with a 6.9% risk of recurrence in patients with mETE (8), a risk that is higher than previously published of up to 5% recurrence rate following lobectomy (20) (21) (22) (23) (24) . These data support the need for change in the treatment guidelines, with selective use of lobectomy and RAI for which criteria should be defined based on the experience of centers that have published their successful experiences with a selective approach (Mayo Clinic, Memorial Sloan-Kettering Cancer Center, and Yonsei University College of Medicine, Korea) (4, 9-11). Regarding mortality, our data support the modifications in the 8th edition of the AJCC classification, in which mETE has no impact on either T category or overall stage (17, 18) . We found no difference in disease-related mortality comparing patients with and without mETE, and, surprisingly, a significantly higher overall mortality in patients without mETE, which is probably a statistical coincidence.
A major source of heterogeneity among the studies in this meta-analysis results from major differences in the definition of mETE. Indeed, an important challenge in the assessment of the impact of mETE is the disagreement among pathologists about the definition of mETE and discordance in its identification (25, 26) . Because the thyroid gland does not have a defined capsule but rather an incomplete, thin fibroadipose pseudocapsule, Mete et al. (26) proposed that involvement of adipose or fibrous tissue does not necessarily indicate ETE of the tumor. Moreover, skeletal muscle involvement is a reliable indication of mETE only in the lateral lobes, because the isthmus does not have a capsule and fibers of strap muscles can be identified in this area (26) . A recent study by Su et al. (25) demonstrated that the pathologic diagnosis of mETE is not easily reproducible, and the overall interpathologist concordance among 11 expert pathologists was poor. These inconsistencies may have a substantial impact on published data regarding risk of recurrence in patients with mETE and support the need for standardization of histopathologic criteria for mETE.
The studies included in our meta-analysis are all retrospective, with quality of evidence that is considered low. We compared groups of patients with and without mETE, which were often unbalanced in baseline characteristics, in which patients with mETE had more aggressive features (e.g., bigger tumor size, higher proportion of patients with N1 disease). This difference in baseline characteristics may result in apparent higher risk of recurrence in patients with mETE, and indeed strengthen our results showing low risk of recurrence in patients with mETE and N0 disease. The subdivision to N0 and N1groups is also somewhat inaccurate because some patients with N1 disease had small central neck metastases detected on prophylactic central neck dissection that have little clinical importance (27) . To improve data quality, future studies should put an emphasis on accurate definition of mETE and meticulous study design with control of confounding factors using tools such as propensity score in large cohorts or matching for baseline characteristics in smaller studies.
In conclusion, based on currently available data, mETE increases risk of recurrence in patients with DTC. However, the increased risk in absolute numbers is small, and in patients with N0 disease, the recurrence risk is within the low risk of recurrence category at 3.5%. mETE has no impact on disease-related mortality and should not change tumor stage.
